Label: REYVOW- lasmiditan tablet

  • NDC Code(s): 0002-0265-04, 0002-0632-04
  • Packager: Eli Lilly and Company
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: CV
  • Marketing Status: Export only

Drug Label Information

Updated January 9, 2023

If you are a consumer or patient please visit this version.

View All Sections
  • PRINCIPAL DISPLAY PANEL

    PACKAGE LABEL - REYVOW 50 mg 4ct carton - FOR EXPORT ONLY

    NDC 0002-0265-04

    4 tablets (1 card of 4 tablets)

    REYVOW™

    (lasmiditan)

    tablets 50 mg

    For oral use.

    Each tablet contains 50 mg of lasmiditan.

    Rx only

    50 mg

    Dispense enclosed Medication Guide to each patient.

    Lilly

    PDP Text – REYVOW 50 mg 8ct carton - FOR EXPORT ONLY
  • PRINCIPAL DISPLAY PANEL

    PACKAGE LABEL - REYVOW 100 mg 4ct carton - FOR EXPORT ONLY

    NDC 0002-0632-04

    4 tablets (1 card of 4 tablets)

    REYVOW™

    (lasmiditan)

    tablets 100 mg

    For oral use.

    Each tablet contains 100 mg of lasmiditan.

    Rx only

    100 mg

    Dispense enclosed Medication Guide to each patient.

    Lilly

    PDP Text – REYVOW 100 mg carton - FOR EXPORT ONLY
  • INGREDIENTS AND APPEARANCE
    REYVOW 
    lasmiditan tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0002-0265
    Route of AdministrationORALDEA ScheduleCV    
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    lasmiditan (UNII: 760I9WM792) (lasmiditan - UNII:760I9WM792) lasmiditan50 mg
    Inactive Ingredients
    Ingredient NameStrength
    Microcrystalline cellulose (UNII: OP1R32D61U)  
    Starch, corn (UNII: O8232NY3SJ)  
    Croscarmellose Sodium (UNII: M28OL1HH48)  
    Sodium Lauryl Sulfate (UNII: 368GB5141J)  
    Magnesium Stearate (UNII: 70097M6I30)  
    Polyvinyl Alcohol, Unspecified (UNII: 532B59J990)  
    Titanium dioxide (UNII: 15FIX9V2JP)  
    Polyethylene Glycol 3350 (UNII: G2M7P15E5P)  
    Talc (UNII: 7SEV7J4R1U)  
    Ferrosoferric Oxide (UNII: XM0M87F357)  
    Product Characteristics
    Colorgray (light gray) Scoreno score
    ShapeOVAL (oval) Size9mm
    FlavorImprint Code L50;4312
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0002-0265-041 in 1 CARTON08/21/2020
    14 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Export only08/21/2020
    REYVOW 
    lasmiditan tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0002-0632
    Route of AdministrationORALDEA ScheduleCV    
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    lasmiditan (UNII: 760I9WM792) (lasmiditan - UNII:760I9WM792) lasmiditan100 mg
    Inactive Ingredients
    Ingredient NameStrength
    Microcrystalline cellulose (UNII: OP1R32D61U)  
    Starch, corn (UNII: O8232NY3SJ)  
    Croscarmellose Sodium (UNII: M28OL1HH48)  
    Sodium Lauryl Sulfate (UNII: 368GB5141J)  
    Magnesium Stearate (UNII: 70097M6I30)  
    Polyvinyl Alcohol, Unspecified (UNII: 532B59J990)  
    Titanium dioxide (UNII: 15FIX9V2JP)  
    Polyethylene Glycol 3350 (UNII: G2M7P15E5P)  
    Talc (UNII: 7SEV7J4R1U)  
    Ferrosoferric Oxide (UNII: XM0M87F357)  
    Ferric Oxide Red (UNII: 1K09F3G675)  
    Product Characteristics
    Colorpurple (light purple) Scoreno score
    ShapeOVALSize12mm
    FlavorImprint Code L100;4491
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0002-0632-041 in 1 CARTON08/21/2020
    14 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Export only08/21/2020
    Labeler - Eli Lilly and Company (006421325)
View All Sections

Find additional resources

(also available in the left menu)

Safety

Report Adverse Events, FDA Safety Recalls, Presence in Breast Milk

Related Resources

Medline Plus, Clinical Trials, PubMed, Biochemical Data Summary

More Info on this Drug

View Labeling Archives, RxNorm, Get Label RSS Feed, View NDC Code(s)NEW!